On the question of antiviral therapy of a new coronavirus infection (COVID-19)

Abstract

Coronavirus infection, or COVID-19 (COronaVIrus Disease 2019), is a new epidemic infectious disease that poses a danger to the population due to its high contagiousness and the development of complications that are unfavorable for the patient’s life, such as ARDS, respiratory and multiple organ failure. The virus has spread worldwide since its detection in Wuhan, Hubei Province, China on December 12, 2019. The World Health Organization (WHO) has declared it a pandemic. Based on the Decree of the Government of the Russian Federation, the new coronavirus COVID-19 (SARS-COV-2) is included in the list of diseases dangerous to society, along with polio and plague. The world community, united by a common goal – to combat the pandemic, is taking measures to actively immunize the entire population through vaccination. However, despite the availability of many vaccines, the number of cases and deaths remains high. As of December 19, 2021, there were 274 644 270 confirmed cases of coronavirus infection in the world and 5 368 822 deaths. Based on the above data, it becomes obvious that the reasonable use of antiviral therapy drugs is necessary for a favorable outcome of the disease of each patient. The review examines the main antiviral drugs proposed by WHO for the treatment of new coronavirus infection (COVID-19). Studies with statistically significant data are selected, which make it possible to fully judge the effectiveness and make it possible to make an adequate decision on the prescription of these drugs. Based on the data obtained from in vitro studies and clinical trials, the prospect of using the above drugs in the treatment of a new coronavirus infection, their effectiveness in clinical practice, as well as the feasibility of using and possible combinations of prescribing these drugs, which can be used to treat and prevent a new coronavirus infection, are considered. The article discusses the effectiveness of the following drugs: remdesvir, interferon, lopinavir and ritonavir, riamilovir, ribavirin, umifenovir, darunavir and cobicistat, favipiravir, chloroquine and hydroxychloroquine, ivermectin and intravenous immunoglobulins.To achieve the goals and objectives of the TB service, a significant role belongs to the average medical staff, where there is a division of functional responsibilities.